Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan; Self-Defense Forces Central Hospital, Tokyo, Japan.
Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Int J Infect Dis. 2021 Oct;111:68-75. doi: 10.1016/j.ijid.2021.08.026. Epub 2021 Aug 15.
The cross-reactive antibody response against seasonal human coronaviruses (HCoVs) was evaluated according to disease severity in patients with COVID-19 in Japan.
In total, 194 paired serum samples collected from 97 patients with COVID-19 (mild, 35; severe, 62) were analyzed on admission and during convalescence. IgG antibodies against the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2 and four seasonal HCoVs (HCoV-NL63, -229E, -OC43, and -HKU1) were detected by enzyme-linked immunosorbent assays.
There was no difference in optical density (OD) values for seasonal HCoVs on admission between the severe and mild cases. In addition, a specific pattern of disease severity-associated OD values for HCoVs was not identified. Significant increases in OD values from admission to convalescence for HCoV-HKU1and -OC43 IgG-S, and for HCoV-NL63 and -229E IgG-N were observed in the severe cases. Significant differences were observed between the mild and severe cases for HCoV-HKU1 and -OC43 IgG-S OD values during convalescence. Correlations were found between the fold changes for HCoV-OC43 IgG-S OD values, and for SARS-CoV-2 IgG-S OD values, and C-reactive protein, lactate dehydrogenase, and lymphocyte levels.
There was no association between the antibody titer for seasonal HCoVs in the early phase of COVID-19 and disease severity.
根据 COVID-19 患者的疾病严重程度,评估了针对季节性人类冠状病毒(HCoV)的交叉反应性抗体应答。
共分析了 97 例 COVID-19 患者(轻症 35 例,重症 62 例)的 194 对入院时和恢复期采集的血清样本。采用酶联免疫吸附试验检测针对 SARS-CoV-2 的核衣壳(N)和刺突(S)蛋白以及 4 种季节性 HCoV(HCoV-NL63、-229E、-OC43 和 -HKU1)的 IgG 抗体。
重症和轻症病例入院时 HCoV 的光密度(OD)值无差异。此外,也未确定与疾病严重程度相关的 HCoV OD 值的特定模式。重症病例入院至恢复期 HCoV-HKU1 和 -OC43 IgG-S 以及 HCoV-NL63 和 -229E IgG-N 的 OD 值显著增加。恢复期重症病例 HCoV-HKU1 和 -OC43 IgG-S OD 值与轻症病例存在显著差异。HCoV-OC43 IgG-S OD 值的倍增值与 SARS-CoV-2 IgG-S OD 值和 C 反应蛋白、乳酸脱氢酶和淋巴细胞水平之间存在相关性。
COVID-19 早期季节性 HCoV 抗体滴度与疾病严重程度无关。